| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702718 | Urologic Oncology: Seminars and Original Investigations | 2017 | 6 Pages |
Abstract
Intratumoral heterogeneity of BAP1 protein expression is more frequent in primary tumor than in metastatic sites. The loss of BAP1 protein expression in metastatic sites predicts poor prognosis in patients with ccRCC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yuji M.D., Naoko M.D., Ph.D., Masaomi M.D., Ph.D., Yu M.D., Ph.D., Ryosuke M.D., Suguru M.D., Chihiro M.D., Yukinori M.D., Yuko M.D., Kazuhiro M.D., Shinji M.D., Ph.D., Tadasu M.D., Ph.D, Toshikazu M.D., Ph.D., Toshimi M.D.,